Design strategies for building drug-like chemical libraries

Current Opinion in Drug Discovery and Development

Volumn 4, Issue 3, 2001, Pages 314-318

  Mitchell, T ^a   Showell, G A ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

ADME; Computational; Drug like; Metabolism; Solubility; Toxicity

Indexed keywords

NEW DRUG;

COMPUTER; DRUG CLEARANCE; DRUG DESIGN; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; HISTOGRAM; REVIEW;

CHEMISTRY; DATABASES, FACTUAL; DRUG DESIGN; PHARMACEUTICAL PREPARATIONS; TOXICOLOGY;

EID: 0034980970     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Computational methods to estimate drug development parameters
2. Computational methods for the prediction of 'drug-likeness'
3. High-throughput screening for lead optimization: A rational approach
4. How can we optimize selection of drug development candidates from many compounds at the discovery stage?
5. Role of pharmacokinetics and metabolism in drug discovery and development
6. Cheminformatics - Predicting the physicochemical properties of 'drug-like' molecules
7. ADME/PK as part of a rational approach to drug discovery
8. Prediction of drug absorption using multivariate statistics
9. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985)
10. Managing the drug discovery/development interface
11. Compound optimization in early- and late-phase drug discovery: Acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens
12. Recognizing molecules with drug-like properties
13. The correlation and prediction of the solubility of compounds in water using an amended solvation energy relationship
14. Prediction of aqueous solubility of organic compounds from molecular structure
15. Estimation of aqueous solubility for a diverse set of organic compounds based on molecular topology
16. Prediction of drug solubility from Monte Carlo simulations
17. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
18. Evaluation and prediction of drug permeation
19. Molecular hashkeys: A novel method for molecular characterization and its importance for predicting important pharmaceutical properties of molecules
20. Prediction of human intestinal absorption of drug compounds from molecular structure
21. QSAR model for drug human oral bioavailability
22. Predicting human oral bioavailability of a compound: Development of a novel quantitative structure-bioavailability relationship
23. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs
24. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach
25. Towards minimalistic modeling of oral drug absorption
26. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties
27. Use and value of metabolism databases
28. Ab initio modeling in the study of drug metabolism
29. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitatitive metabolic predictions using a combined protein and pharmacophore model for CYP2D6
30. bm3)
31. Mammalian microsomal cytochrome P450 monooxygenase: Structural adaptations for membrane binding and functional diversity
32. The prediction of human clearance from hepatic microsomal metabolism data
33. Use of FDA databases and computational toxicology to estimate potential toxicity
34. Computational methods for the prediction of drug toxicity
35. Drug-like index: A new approach to measure drug-like compounds and their diversity
36. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known databases
37. A scoring scheme for discriminating between drugs and non-drugs
38. Can we learn to distinguish between 'drug-like' and 'non-drug-like' molecules?
39. Improving the odds in discriminating 'drug-like' from 'non-drug-like' compounds
40. Potential drugs and non-drugs: Prediction and identification of important structural features
41. Trials and tribulations of developing predictive models for ADME